Since a soluble form of IL-27Rα—sIL-27RA—has been described to naturally control IL-27 receptor binding [228] and treatment with recombinant sIL-27RA has a beneficial effect in septic peritonitis [229], adjunct treatment with sIL-27RA also constitutes an interesting future option to improve the therapy for TB. This evidence concerns the gene IL27RA and tuberculosis.